About Sirna Therapeutics
Sirna Therapeutics is a Healthcare company based in San Francisco (United States) founded in 1992, and was acquired by Alnylam in January 2014. It develops RNAi-based therapies. It operates in the Healthcare and Technology sectors. Its focus areas include Life Sciences, Gene Therapy, RNA and siRNA. Its legal entity is SIRNA THERAPEUTICS INC. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Sirna Therapeutics is a biotechnology company that develops therapeutics based on RNA interference (RNAi) technology. The company develops small interfering RNA (siRNA) drugs. The company started a clinical trial of its siRNA-based treatment for age-related macular degeneration. The company went public in 2008. Sirna Therapeutics is a biotechnology company exploring the use of RNA interference in human disease therapy. The company was acquired by Merck Co. in 2006 for 1.1B. In 2014, Sirna was acquired by Alnylam from Merck for 175M.
Funding Insights of Sirna Therapeutics
- Total Rounds 3
- Last Round Post-IPO — $28.01M
- First Round $48M
(Apr 2003)
- Investors Count 5
All 3 funding rounds of Sirna Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2005 | $28.01M | Post-IPO | – | – | |
| May 2004 | $18.72M | Post-IPO | – | – | – |
| Apr 2003 | $48M | Post-IPO | – | – |
6 investors in total: 6 institutional.
Investors in Sirna Therapeutics
Sirna Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Alnylam, Credit Suisse and Oxford Bioscience Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage VC firm investing in the US and Korea | oxbio.com | Boston, United States | ||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Venture capital is invested in cybersecurity, fintech, and AI startups. | ggvc.com | Menlo Park, United States | ||
Wealth management, asset management, and investment banking services are offered. | 1856 | credit-suisse.com | Zurich, Switzerland | |
| tvmvc.com | ||||
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | alnylam.com | Cambridge, United States |
Investor details for Sirna Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Sirna Therapeutics
4 dated milestones of Sirna Therapeutics across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Sirna Therapeutics is founded.
- Funding First funding round of $48.0M.
- Funding Latest funding round, Post-IPO, of $28.0M.
- Exit Acquired by Alnylam.
Competitors of Sirna Therapeutics
Sirna Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Sirna Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Sirna Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sirna Therapeutics
Sirna Therapeutics was founded in 1992 and raised its 1st funding round 11 years after it was founded.
Sirna Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Sirna Therapeutics is a biotechnology company that develops therapeutics based on RNA interference (RNAi) technology. The company develops small interfering RNA (siRNA) drugs. The company started a clinical trial of its siRNA-based treatment for age-related macular degeneration. The company went public in 2008. Sirna Therapeutics is a biotechnology company exploring the use of RNA interference in human disease therapy. The company was acquired by Merck Co. in 2006 for 1.1B. In 2014, Sirna was acquired by Alnylam from Merck for 175M.
Sirna Therapeutics's top competitors include BridgeBio, Forge Biologics and Insitro.
Sirna Therapeutics has 6 investors. Key investors include Alnylam, Credit Suisse, Oxford Bioscience Partners, Venrock, and GGV Capital.
Sirna Therapeutics operates through Sirna Therapeutics Inc.
Yes. Sirna Therapeutics was acquired by Alnylam in January 2014.